NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Illumina were up 6.6 percent, or $.89, at $14.49 in mid-afternoon trading after the company announced positive third-quarter results yesterday.
As GenomeWeb News reported yesterday, Illumina had a 44-percent increase in third-quarter revenues and narrowed its quarterly net loss to $1.4 million from $2 million from a year ago. Illumina credited the increase in revenue to a "record" number of BeadStations shipped during the quarter.
Today, Illumina said it has sold a BeadStation system to PharmacoDesign that gives Illumina exclusive, licensed access to biomarkers discovered through disease studies.
Separately today, Illumina has asked the US Patent and Trademark Office to investigate the validity of a patent currently owned by Affymetrix that Illumina claims its scientists had originally invented.